These findings uncover a TP53 mutation-β-catenin-ΔNp63-GPX4 axis that drives ferroptosis resistance and glioma malignancy, highlighting ΔNp63 as a potential therapeutic target in TP53-mutant GBM. This evidence concerns the gene TP53 and central nervous system cancer.